免疫检查点抑制剂治疗MSI-H/dMMR转移性结直肠癌中的假性进展
BACKGROUND: The efficacy of immune checkpoint inhibitors (ICIs) in microsatellite instability-high/DNA mismatch repair (MSI/dMMR) metastatic colorectal cancer (mCRC) is well established. ICIs are responsible for pseudoprogression (PSPD) that complicates clinical decisions.…
要点
- MSI-H/dMMR mCRC接受ICI治疗时假性进展发生率为10%。
- 假性进展均发生在治疗前3个月内,中位时间5.7周。
- 假性进展患者中8例获得客观缓解,2年PFS率70.0%。
核心结论
- MSI-H/dMMR mCRC患者接受ICI治疗可发生假性进展,且均出现在前3个月内,占原发影像学进展的大多数。
主要发现
- 假性进展发生率在单药抗PD-1组为14.8%(9/61),抗PD-1联合抗CTLA-4组为4.8%(3/62)。
- 8例假性进展患者获得客观缓解,假性进展患者2年无进展生存率70.0%(95%CI 32.9-89.2),总生存率75.0%(95%CI 29.8-93.4)。
关键数值与推荐
- 假性进展定义为iRECIST下未确认的疾病进展。
- 29例患者在RECIST 1.1进展后继续接受ICI治疗。
临床怎么用
- MSI-H/dMMR mCRC患者ICI治疗后3个月内出现影像学进展时,应结合iRECIST评估假性进展可能,避免过早停药。
- 3个月后影像学进展按iRECIST标准评估假性进展的意义可能有限。
局限性
- 回顾性单中心研究,样本量有限。
- 假性进展亚组事件数少,生存率置信区间宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of immune checkpoint inhibitors (ICIs) in microsatellite instability-high/DNA mismatch repair (MSI/dMMR) metastatic colorectal cancer (mCRC) is well established. ICIs are responsible for pseudoprogression (PSPD) that complicates clinical decisions. We evaluated the PSPD frequency in patients with MSI/dMMR mCRC treated with ICIs. PATIENTS AND METHODS: Consecutive patients with MSI/dMMR mCRC treated with ICIs from February 2015 to December 2019 at Saint-Antoine Hospital were included. Imaging was retrospectively and centrally reviewed according to Response Evaluation Criteria in Solid Tumours, version 1.1 (RECIST 1.1) and immune RECIST (iRECIST). PSPD was defined as an unconfirmed disease progression by iRECIST. RESULTS: One hundred twenty-three patients with MSI/dMMR mCRC were included. Thirty-six patients (29%) had radiological PD according to RECIST 1.1 during the median follow-up of 22.3 months (95% confidence interval [CI], 1.5-62.2), including 22 in the first 3 months (the primary radiological PD). Twenty-nine patients continued ICIs beyond PD. Twelve patients experienced PSPD, representing 10% of the population and 52% of the primary radiological PD. The median time to PSPD was 5.7 weeks (95% CI, 4.1-11.4). No PSPD was observed after 3 months. The PSPD incidence was 14.8% in patients treated with anti-PD1 alone (n = 9/61) and 4.8% in case of anti-PD1 plus anti-CTLA-4 (n = 3/62). Eight patients with PSPD experienced an objective response. The 2-year progression-free survival and overall survival rates for patients with PSPD were 70.0% (95% CI, 32.9-89.2) and 75.0% (95% CI, 29.8-93.4), respectively. CONCLUSION: Patients with MSI/dMMR mCRC treated with ICIs experienced PSPDs. PSPD occurred within the first 3 months and represented most of the primary radiological PDs. The use of iRECIST criteria should be questioned after 3 months.
引用
- Colle R, Radzik A, Cohen R, et al. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Eur J Cancer. 2020. PMID: 33316636. doi:10.1016/j.ejca.2020.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。